Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders

Author(s): Rodrigo Machado-Vieira, Giacomo Salvadore, Lobna A. Ibrahim, Nancy Diaz-Granados, Carlos A. Zarate Jr..

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 14 , 2009

Become EABM
Become Reviewer

Abstract:

There have been no recent advances in drug development for mood disorders in terms of identifying drug targets that are mechanistically distinct from existing ones. As a result, existing antidepressants are based on decades-old notions of which targets are relevant to the mechanisms of antidepressant action. Low rates of remission, a delay of onset of therapeutic effects, continual residual depressive symptoms, relapses, and poor quality of life are unfortunately common in patients with mood disorders. Offering alternative options is requisite in order to reduce the individual and societal burden of these diseases. The glutamatergic system is a promising area of research in mood disorders, and likely to offer new possibilities in therapeutics. There is increasing evidence that mood disorders are associated with impairments in neuroplasticity and cellular resilience, and alterations of the glutamatergic system are known to play a major role in cellular plasticity and resilience. Existing antidepressants and mood stabilizers have prominent effects on the glutamate system, and modulating glutamatergic ionotropic or metabotropic receptors results in antidepressant-like properties in animal models. Several glutamatergic modulators targeting various glutamate components are currently being studied in the treatment of mood disorders, including release inhibitors of glutamate, N-methyl-D-aspartate (NMDA) antagonists, alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) throughput enhancers, and glutamate transporter enhancers. This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators.

Keywords: AMPA, antidepressant, bipolar disorder, depression, drug development, glutamate, metabotropic, NMDA

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 15
ISSUE: 14
Year: 2009
Page: [1595 - 1611]
Pages: 17
DOI: 10.2174/138161209788168010
Price: $58

Article Metrics

PDF: 6